Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.
Employment agreement with Pursglove has $240K annual salary, plus potential bonus and stock option grant for 350K shares.
Van der Baan's existing stock option for 250K shares fully vested; exercise period extended to one year after service ends.
Pursglove's appointment automatically terminates if Lixte fails to complete a financing enabling Nasdaq listing by July 3, 2025.
If financing condition not met, van der Baan to be reinstated as CEO and Chairman, and Pursglove's option grant cancelled.

item 1.01item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Bastiaan van der Baan

President and Chief Scientific Officer

LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Effective: 2025-06-16
Successor: Geordan Pursglove
Filed: Jun 17, 2025 23:59 UTC

Bastiaan van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer

Appointed

Geordan Pursglove

Chief Executive Officer and Chairman

LIXT · LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Effective: 2025-06-16
Filed: Jun 17, 2025 23:59 UTC

effective June 16, 2025, Geordan Pursglove was appointed as the Company’s Chairman of the Board of Directors and Chief Executive Officer,

Source: SEC EDGAR

accession 0001641172-25-015346

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.